Carbonic anhydrases XIV (CA XIV) is responsible for health issue and a therapeutic target of many disorders
like epilepsy, and retinopathy. Here we described the first pharmacophore model for human CA XIV to identify the new
scaffolds compounds. Hypotheses 1, with the highest cost difference, best correlation coefficient as well as the lowest
RMSD, was validated by test set and Fischer method. Then, Hypotheses 1 was used for virtual screening in 718361 databases
compounds. After Lipinski’s rule of five and ADMET properties, 148 compounds with high potential activity were
filtered and estimated by docking. Finally, 6 new scaffold compounds turned out to be potential as new class CA XIV antagonists.
In addition, we also analyzed the interaction between compound 7 and ten CA isoforms and explained various
inhibitions caused by their distinct residues. Therefore, this paper could be helpful in novel CA XIV inhibitors discovery
and its selective inhibitors design.
Keywords: Carbonic anhydrase XIV, Molecular docking, Pharmacophore model, Selective inhibitor, Virtual screening, 3DQSAR.
Rights & PermissionsPrintExport
Published on: 11 March, 2014
Page: [403 - 412]